The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Four top stocks have at least a 4% dividend and make sense for investors who may be worried about increased volatility in the ...

The approval of etanercept for juvenile idiopathic arthritis in 1999 heralded a new era for children with arthritis. However, ...

Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, ...

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...

Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.

Mary-Claire King, a groundbreaking innovator in genetics, received The National Academy of Sciences' most prestigious metal.